The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
The Botox maker will pay up to $1.7 billion for Tobira, the developer of an experimental treatment for a nonalcoholic fatty liver condition.
The defendants allegedly made $234,000 by trading in Pharmasset shares based on nonpublic information about a takeover offer.
